EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Fintepla…Original Article
FDA Approves Fintepla (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
